NCT07209631Completed
Serum Lipoprotein-a as a Marker of Severity of Coronary Artery Disease in Aortic Valve Sclerosis Patients
Is Lipoprotein-a Just a Lipid Marker or a Predictor for the Severity of Coronary Lesions in Aortic Valve Sclerosis Patients?
Source: ClinicalTrials.gov · Last updated 7 Oct 2025
Brief summary (registry, in English)
This work aimed to evaluate the association of serum level of Lp(a) with the severity of coronary artery disease (CAD) in aortic valve sclerosis (AVS) patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 29 Sept 2025
- Start date
- 1 Oct 2024
- Primary completion date
- 1 May 2025
- Lead sponsor
- Sohag University
- Diseases
- Coronary artery disease
- NCT number
- NCT07209631
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 1 Oct 2024 to the primary completion date, 1 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Administration of anti-inflammatory or immunosuppressive drugs.
Other illness
- Severe chronic kidney failure.
Other
- Aortic stenosis.
- Aortic prosthesis.
- Untreated hypothyroidism.
- Pregnancy.
Who the study is looking for
- Age ≥ 18 years.
- Both sexes.
- Patients with chest pain and/or dyspnea were diagnosed provisionally as having coronary artery disease.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sohag University Coordinator of this site? Confirm its status | Sohag | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.